Racing rival Pfizer, Merck’s Vaxneuvance makes its case for an FDA approval in children
Time is of the essence for Merck as the company races with rival Pfizer to gain an FDA approval for its next-generation pneumococcal vaccine in children.
The longer ...
Continue Reading →
